Advertisement

Topics

FDA backs Novo's diabetes drug for cardiovascular efficacy

04:24 EDT 21 Jun 2017 | Pharmafile

Good news for Novo Nordisk as the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommends that data from a recent study into Victoza’s (liraglutide) efficacy in reducing cardiovascular risk should be included on the drug’s label.

read more

Original Article: FDA backs Novo's diabetes drug for cardiovascular efficacy

NEXT ARTICLE

More From BioPortfolio on "FDA backs Novo's diabetes drug for cardiovascular efficacy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...